Goldman Sachs’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.38M Buy
634,655
+546,722
+622% +$2.9M ﹤0.01% 4253
2026
Q2
$426K Buy
+87,933
New +$378K ﹤0.01% 5798
2024
Q3
– Sell
-224,185
Closed -$482K – 5801
2024
Q2
$482K Buy
224,185
+195,815
+690% +$466K ﹤0.01% 4854
2024
Q1
$92.2K Buy
28,370
+14,324
+102% +$156K ﹤0.01% 5252
2023
Q4
$288K Buy
+14,046
New +$235K ﹤0.01% 5025
2023
Q3
– Sell
-39,107
Closed -$332K – 5523
2023
Q2
$332K Buy
+39,107
New +$281K ﹤0.01% 4962
2022
Q2
– Sell
-19,497
Closed -$294K – 6438
2022
Q1
$294K Buy
+19,497
New +$296K ﹤0.01% 5669

Other funds holding ANTX

Goldman Sachs's ANTX Position: Q3 2026 in Review

Goldman Sachs increased its AN2 Therapeutics (ANTX) stake by 622% in Q3 2026, buying an estimated $2.9M and bringing the position to 634,655 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4253.

Goldman Sachs first reported a position in ANTX in Q1 2022 and has held it in 7 quarters since. 84 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Goldman Sachs held 634,655 shares of AN2 Therapeutics worth $3.38M as of Q3 2026.
  • Goldman Sachs bought 546,722 AN2 Therapeutics shares in Q3 2026, an estimated $2.9M.
  • AN2 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #4253 holding.
  • Goldman Sachs first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • 84 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.